Lonsurf extends life by roughly 1.5 to 2 months compared to placebo in late-stage colorectal and gastric cancers. Whether that tradeoff feels “worth it” depends on your specific situation: how well you tolerate the side effects, whether you combine it with other treatments, and what your goals are for the time you have. Here’s what the data actually shows so you can weigh the decision clearly.
How Much Extra Time Lonsurf Provides
In the landmark RECOURSE trial for metastatic colorectal cancer, patients taking Lonsurf lived a median of 7.1 months compared to 5.3 months on placebo. That’s about a 1.8-month improvement, with a 32% reduction in the risk of death. These were patients who had already tried and failed at least two prior treatment regimens, so this is a last-line therapy where the bar for “benefit” is different from earlier-stage treatment.
For metastatic gastric cancer, the picture is similar. Median overall survival was 5.7 months with Lonsurf versus 3.6 months with placebo, a gain of about 2.1 months and a 31% reduction in the risk of death.
These are median numbers, meaning half of patients did better and half did worse. Some people get considerably more time than the median suggests, while others see little benefit. The statistics tell you what’s likely across a large group, not what will happen to you specifically.
The Combination That Changes the Calculation
A more recent trial called SUNLIGHT tested Lonsurf paired with bevacizumab (a drug that blocks blood vessel growth to tumors) against Lonsurf alone in metastatic colorectal cancer. The combination pushed median survival to 10.8 months, compared to 7.5 months for Lonsurf by itself. That’s a 3.3-month improvement from adding bevacizumab, and it brought the total survival benefit over placebo closer to 5 months.
The FDA approved this combination in 2023, and it has become the preferred approach for many oncologists. If your doctor is recommending Lonsurf, it’s worth asking whether the combination is an option for you, since the survival data is substantially better.
Side Effects You Should Expect
Lonsurf’s main side effects involve your blood cells. In the RECOURSE trial, 38% of patients developed severe neutropenia, meaning dangerously low white blood cell counts that increase infection risk. Severe anemia occurred in 18% of patients, and severe drops in platelets (which help with clotting) affected about 5%.
When combined with bevacizumab, severe neutropenia rates climb to 52%. Interestingly, severe anemia and low platelets were actually less common with the combination (5% and 4%, respectively), though the reasons for that aren’t entirely clear.
In practical terms, neutropenia means your doctor will monitor your blood counts regularly and may delay or reduce doses. You’ll need to be vigilant about infections, since even a minor cold can become serious when your immune system is suppressed. Many patients manage these side effects well enough to stay on treatment, but some need dose reductions or breaks that can affect how much drug they actually receive.
Compared to regorafenib (the other main option at this stage of treatment), Lonsurf has a different side effect profile. Regorafenib is more likely to cause painful hand-foot skin reactions, liver enzyme elevations, and fatigue, while Lonsurf hits your blood counts harder. In a retrospective study comparing the two, treatment discontinuation due to toxic effects was more common with regorafenib, and patients were able to maintain a higher percentage of their intended Lonsurf dose (83% versus 54% for regorafenib). That matters because staying on treatment longer generally means more benefit.
How Lonsurf Compares to Regorafenib
If you’re weighing Lonsurf against regorafenib, the survival data is essentially a wash. In a study that gave patients both drugs in sequence, median overall survival was 9.3 months when starting with Lonsurf and 9.1 months when starting with regorafenib. The order didn’t matter, and neither drug showed a clear advantage over the other in terms of how long people lived.
The real difference comes down to tolerability. Lonsurf is taken twice daily for five days on, two days off, for two weeks, followed by a two-week rest, repeating in 28-day cycles. Regorafenib is taken once daily for three weeks with one week off. Patients generally found it easier to maintain their full Lonsurf dose, while regorafenib often required dose reductions (most patients in the study started at a reduced dose of 120 mg instead of the standard 160 mg).
The choice between the two often comes down to which side effects you and your oncologist are more comfortable managing. If you’re prone to skin problems or liver issues, Lonsurf may be the better fit. If your blood counts are already borderline, regorafenib might make more sense.
What the Dosing Schedule Looks Like
Lonsurf is an oral pill, which is a meaningful advantage over intravenous chemotherapy. The standard dose is 35 mg per square meter of body surface area, taken twice a day. You take it on days 1 through 5 and days 8 through 12 of each 28-day cycle, then rest for the remaining two weeks. That means you’re actively taking pills for 10 out of every 28 days.
This schedule allows your blood counts to recover between active periods. Some oncologists are also exploring biweekly dosing schedules that may reduce the severity of blood count drops while maintaining similar effectiveness, though the standard schedule remains the most well-studied approach.
Cost and Access
Lonsurf is expensive, as most cancer drugs are. The exact out-of-pocket cost varies widely depending on your insurance, but it can run thousands of dollars per month without coverage. Taiho Oncology, the manufacturer, offers a Patient Assistance Program for those who qualify financially. Medicare Part D patients who fall below 150% of the federal poverty level need to first apply for the Low-Income Subsidy program before accessing manufacturer assistance.
If cost is a concern, ask your oncology team about financial counseling. Most cancer centers have specialists who can help navigate assistance programs, copay support, and insurance appeals. The financial burden of treatment is a legitimate factor in deciding whether Lonsurf is worth it for you, and no one should feel guilty about weighing it.
Putting It All Together
A median gain of 1.8 months with Lonsurf alone, or potentially closer to 5 months with the bevacizumab combination, is modest in absolute terms. But context matters enormously here. This is a treatment for people who have exhausted other options. At this stage, the goals of treatment shift from curing the cancer to maintaining quality of life and extending meaningful time.
Some patients find that even a few extra months allow them to reach milestones that matter deeply: a grandchild’s birth, a holiday, a conversation they needed to have. Others decide that the side effects and medical appointments aren’t how they want to spend their remaining time. Both are reasonable conclusions, and the “right” answer is personal. The data gives you the framework, but only you can decide what those months are worth.